Advertisement
Document › Details
Merck KGaA. (12/11/17). "Press Release: Merck Signs Distribution Agreement with Avanti Polar Lipids". Darmstadt.
Region | ww excl US | |
Organisation | Merck Life Science Business (MilliporeSigma in US) | |
Group | Merck (DE) (Group) | |
Organisation 2 | Avanti Polar Lipids Inc. | |
Product | research reagent | |
Product 2 | lipidomics | |
Person | Bischoff, Klaus (Merck (D) 200802 Head Performance & Life Science Chemicals division) | |
> Merck to distribute top lipid portfolio outside of United States
> Improves customer access through e-commerce platform
Merck, a leading science and technology company, today announced that it has entered into an agreement with Avanti® Polar Lipids to be the exclusive multinational distributor of the USA-based company’s research lipids portfolio outside of the United States.
Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise to distribute Avanti® Polar Lipids research lipid portfolio. The distribution agreement includes all geographies worldwide except for the United States, where Avanti® Polar Lipids will continue to reach customers via its own channels. Financial details were not disclosed.
“High-quality lipids are an essential component of precision in the laboratory,” said Klaus Bischoff, Head of the Research Solutions business area, Life Science at Merck. “Avanti® Polar Lipids’ research lipids strengthen Merck’s overall Life Science portfolio, giving our customers access to a broad portfolio of the highest purity lipids on the market.”
Merck offers a complete portfolio of products and solutions that enable scientific discovery, including life science reagents and kits, lab and specialty chemicals and lab separation and workflow tools.
Avanti® Polar Lipids is a leading manufacturer and supplier of the highest purity lipids for research and pharmaceutical product development. Through this agreement, customers outside of the United States will have enhanced, on-demand access to the Avanti® research lipid portfolio through the life science business of Merck’s robust e-commerce platform, SigmaAldrich.com, regional inventory and company sales representatives. Products will be stocked globally for improved availability to customers.
Transition of approximately 2,000 products from the Avanti® research lipid portfolio to Merck is expected to be completed in early 2018. In the interim, these products will continue to be available through existing Avanti® Polar Lipids’ channels.
Avanti® lipidomics products included in this agreement provide a new approach to answer fundamental questions about lipid structure and function and meet the demands of lipid researchers. For more information, visit www.SigmaAldrich.com/Avanti.
For more information, contact Karen Tiano
+49 6151 72 44461
All Merck news releases are distributed by email at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of €15 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck holds the global rights to the “Merck” name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
Record changed: 2023-06-05 |
Advertisement
More documents for Merck (DE) (Group)
- [1] Caris Life Sciences Inc.. (4/4/24). "Press Release: Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development". Irving, TX....
- [2] BioGeneration Ventures B.V.. (4/2/24). "Press Release: BGV Appoints Peter Halle, PhD as Venture Partner". Amsterdam....
- [3] C4 Therapeutics, Inc.. (3/4/24). "Press Release: C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins". Watertown, MA....
- [4] Precirix N.V.. (2/29/24). "Press Release: Tom Plitz Commences Role as Chief Executive Officer of Precirix". Brussels....
- [5] Merck KGaA. (1/4/24). "Press Release: Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [6] ITM Isotope Technologies Munich SE. (12/14/23). "Press Release: ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics". Garching....
- [7] Merck KGaA. (12/4/23). "Press Release: Merck Strengthens Oncology Portfolio through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib [Not intended for UK-, US- or Canada-based media]". Darmstadt....
- [8] Merck KGaA. (11/21/23). "Press Release: Merck Expands Newest Biologics Testing Center in Shanghai". Shanghai....
- [9] Merck KGaA. (11/14/23). "Press Release: Merck Announces Plans for New U.S. Healthcare Headquarters in Boston’s Seaport District [Not intended for US-based media]". Darmstadt....
- [10] Merck KGaA. (10/30/23). "Press Release: Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate [Not intended for US-, Canada- or UK-based media]". Darmstadt...
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top